Klivira
Request demo

Streamlining Tezspire Prior Authorization for Cardiology Practices

Navigating Tezspire prior authorization for cardiology patients with complex comorbidities presents unique administrative challenges. Klivira's platform is designed to automate and simplify these intricate specialty drug PA workflows.

While Tezspire is primarily indicated for severe asthma, cardiology practices frequently manage patients with complex health profiles and comorbidities. For these patients, coordinating prior authorization for specialty drugs prescribed by other specialties, such as Tezspire, becomes a critical component of care delivery and revenue cycle management. Efficiently managing these PAs, even when not the primary prescribing specialty, is essential to prevent treatment delays and financial impact.

Understanding Tezspire's Prior Authorization Landscape

Tezspire (tezepelumab-ekko) is a high-cost biologic, an anti-TSLP monoclonal antibody, approved for severe asthma. As a specialty drug, it is subject to extensive prior authorization requirements across commercial, Medicare Advantage, and Medicaid managed care plans. Cardiology practices, in their role managing patients with multiple chronic conditions, may need to coordinate or support PA processes for patients on Tezspire, ensuring seamless care transitions and preventing administrative burdens.

Navigating Specialty Drug Prior Authorization in Cardiology

Cardiology practices encounter significant prior authorization volume for advanced cardiac imaging, interventional procedures, and specialty cardiovascular drugs. When patients also require specialty medications like Tezspire for co-existing conditions, the complexity compounds. Klivira's platform centralizes these diverse PA requirements, whether they pertain to cardiac procedures or specialty drug coordination, integrating with EMRs to provide a unified workflow.

Key Documentation for Tezspire Prior Authorization

  • Confirmation of severe asthma diagnosis (e.g., FEV1, exacerbation history).
  • Documentation of prior asthma therapies (e.g., high-dose inhaled corticosteroids, LABAs, other biologics) and their failure or contraindications.
  • Relevant laboratory results (e.g., eosinophil counts, FeNO levels) as per payer-specific criteria.
  • Clinical notes detailing patient symptoms, functional limitations, and impact of asthma on daily life.
  • Payer-specific forms and attestations, often routed through ePA or specialty benefit-management vendors.

Common Prior Authorization Hurdles for Specialty Medications like Tezspire

Denials for specialty drugs often stem from unmet step therapy requirements, insufficient documentation of disease severity, or lack of adherence to guideline-directed medical therapy for the primary indication. For Tezspire, this typically involves demonstrating failure of conventional asthma treatments or specific biomarker thresholds. Cardiology practices supporting these PAs must ensure comprehensive records are accessible and align with payer medical policies, which Klivira facilitates through intelligent workflow automation.

Klivira's Approach to Complex Prior Authorization Workflows

Klivira's platform provides robust support for specialty drug prior authorization, including those managed by specialty benefit-management vendors. Our system identifies and routes requests correctly, applying payer-specific logic for conditions like severe asthma. For cardiology, this means streamlined management of all PA types, from advanced cardiac imaging to specialty medications, reducing the administrative burden on your team and accelerating patient access to necessary treatments.

Frequently asked questions

Why would a cardiology practice need to manage Tezspire prior authorization?

Cardiology practices frequently care for patients with multiple comorbidities, including severe asthma. While Tezspire is prescribed by pulmonology or allergy/immunology, cardiology staff may need to coordinate or assist with the prior authorization process to ensure continuity of care and prevent delays for their shared patients.

What are common challenges for specialty drug PA like Tezspire?

Specialty drugs often have stringent PA requirements, including specific diagnostic criteria, documentation of prior therapy failures (step therapy), and specific lab values. These complexities, combined with varying payer policies and the involvement of specialty benefit-management vendors, can lead to high administrative burden and denial rates.

Does Klivira integrate with EMRs for Tezspire PA?

Yes, Klivira integrates seamlessly with major EMR systems using standards like SMART on FHIR. This integration allows for automated extraction of necessary clinical data, reducing manual data entry and improving the accuracy and efficiency of prior authorization submissions for all medications, including specialty drugs like Tezspire.

How does Klivira handle payer-specific requirements for specialty drugs?

Klivira's platform incorporates a comprehensive library of payer medical policies and leverages AI to apply payer-specific criteria dynamically. This ensures that Tezspire prior authorization requests are submitted with the correct documentation and follow the precise guidelines required by each individual health plan, whether submitted via X12 278, ePA, or payer portals.

What clinical guidelines are relevant for Tezspire approval?

Approval for Tezspire is typically based on guidelines for severe asthma, such as those from the Global Initiative for Asthma (GINA). These guidelines inform payer medical policies regarding diagnosis, disease severity, and required prior therapies. Cardiology practices supporting these PAs should be aware of these criteria for effective coordination.

Related coverage

Other tezspire prior authorization by payer

Other tezspire prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo